ARDX - Ardelyx, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.02
-0.77 (-8.76%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.79
Open8.77
Bid7.01 x 2200
Ask8.03 x 1400
Day's Range7.93 - 8.77
52 Week Range2.10 - 8.81
Volume1,430,234
Avg. Volume1,061,063
Market Cap527.775M
Beta (5Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday, Feb. 26, 2020 in New York City.

  • PR Newswire

    Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000. In addition, Ardelyx has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 9, 2019, subject to customary closing conditions.

  • PR Newswire

    Ardelyx Announces Proposed Public Offering of Common Stock

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • PR Newswire

    Ardelyx Announces Presentation at Kidney Week 2019

    Late breaking oral presentation to highlight data from AMPLIFY, the Pivotal Phase 3 Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment ...

  • PR Newswire

    Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights

    PHREEDOM clinical trial to read out this quarter FREMONT, Calif. , Nov. 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class ...

  • PR Newswire

    Ardelyx to Host Analyst Day in New York

    Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-C FREMONT, Calif. , Oct. 10, 2019 /PRNewswire/ ...

  • PR Newswire

    Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Ladenburg Thalmann Conference on Tuesday, September 24, 2019 at 9:00 a.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the lives of people with cardiorenal diseases by developing first-in-class medicines that matter.

  • PR Newswire

    Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

    FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that the U.S. Food and Drug Administration has approved IBSRELA® (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients.

  • PR Newswire

    Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

    Tenapanor in combination with binders met the primary endpoint demonstrating a statistically significant (p=0.0004) reduction of serum phosphorus compared to binders alone. Approximately two times more patients achieved the established serum phosphorus treatment goal of less than 5.5mg/dL in the tenapanor arm compared to binders alone (p -values≤0.0097) for each week of treatment. FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive results from AMPLIFY, a pivotal Phase 3 study of tenapanor in combination with phosphate binders in patients with chronic kidney disease (CKD) on dialysis whose hyperphosphatemia was not previously controlled with binders alone.

  • PR Newswire

    Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study

    FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, September 3, at 8:30 am Eastern Time to review the results from the pivotal Phase 3 AMPLIFY study of tenapanor in combination with phosphate binders in patients with chronic kidney disease on dialysis whose hyperphosphatemia was not controlled with binders. Tenapanor is Ardelyx's investigational, first-in-class, small molecule, non-binder, phosphate absorption inhibitor. To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 9789472.

  • PR Newswire

    Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights

    AMPLIFY clinical trial to read out 3Q19 PHREEDOM clinical trial to read out 4Q19 FREMONT, Calif. , Aug. 9, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused ...

  • PR Newswire

    Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference

    FREMONT, Calif., May 30, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2019 at 9:00 a.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines.

  • PR Newswire

    Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights

    Two Pivotal Phase 3 readouts in 2H 2019 FREMONT, Calif. , May 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines ...

  • PR Newswire

    Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors

    Dr. Block is one of the world's preeminent nephrologists and a trailblazer in leading clinical development for drugs focused on enhancing the care and treatment of patients suffering from chronic kidney disease (CKD) and end stage renal disease (ESRD) patients on dialysis. Dr. Block has participated extensively in guiding the development of tenapanor, Ardelyx's lead product candidate in Phase 3 clinical trials for the treatment of hyperphosphatemia in ESRD patients on dialysis.

  • PR Newswire

    Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

    FREMONT, Calif., March 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced the publication in the Journal of the American Society of Nephrology (JASN) of results from the first of two Phase 3 pivotal trials for tenapanor to treat hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. During the treatment period, 164 patients completed treatment in one of three randomized dosing groups (3, 10 and 30 mg titration) of tenapanor twice daily.

  • PR Newswire

    Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

    Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif. , March 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused ...